In other cancer types, inhibiting the CCL2/CCR2 axis with CCR2 inhibitors or anti-CCL2 antibodies has demonstrated reduced myeloid cell recruitment and improved clinical outcomes [190–192]. The gene discussed is CCL2; the disease is cancer.